Symbols / SEELQ $0.00 +0.00%
SEELQ Chart
About
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 58.00 |
| Enterprise Value | 9.86M | Income | 4.09M | Sales | 2.01M |
| Book/sh | -135.50 | Cash/sh | 0.79 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | 0.00 | Forward P/E | — | PEG | — |
| P/S | 0.00 | P/B | -0.00 | P/C | — |
| EV/EBITDA | — | EV/Sales | 4.90 | Quick Ratio | 0.02 |
| Current Ratio | 0.08 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.20 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 11.90% | Earnings | 2023-11-14 16:00 | ROA | -261.11% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -8.35% | Profit Margin | 203.13% | Shs Outstand | 581.00K |
| Shs Float | 359.03K | Short Float | 29.52% | Short Ratio | 0.14 |
| Short Interest | — | 52W High | 0.01 | 52W Low | 0.00 |
| Beta | 24.92 | Avg Volume | 897.00 | Volume | 100.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-1062.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
- Seelos Therapeutics files for Chapter 11 bankruptcy - Investing.com Fri, 22 Nov 2024 08
- Amylyx Pharmaceuticals: A High Risk/High Reward Stock (NASDAQ:AMLX) - Seeking Alpha Mon, 11 Sep 2023 07
- Seelos Therapeutics (SEEL) Stock Price, News & Analysis $SEEL - MarketBeat hu, 04 Apr 2019 01
- GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). - marketscreener.com ue, 21 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -40.24M | -70.74M | -61.56M |
| TotalUnusualItems | 2.49M | -2.73M | -2.89M |
| TotalUnusualItemsExcludingGoodwill | 2.49M | -2.73M | -2.89M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.88M | -73.53M | -66.05M |
| ReconciledDepreciation | 57.00K | 53.00K | 0.00 |
| EBITDA | -37.75M | -73.47M | -64.45M |
| EBIT | -37.81M | -73.52M | -64.45M |
| NetInterestIncome | 123.00K | 107.00K | -1.49M |
| InterestExpense | 75.00K | 14.00K | 1.60M |
| InterestIncome | 198.00K | 121.00K | 113.00K |
| NormalizedIncome | -40.38M | -70.81M | -63.15M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.88M | -73.53M | -66.05M |
| TotalExpenses | 40.50M | 70.92M | 61.67M |
| TotalOperatingIncomeAsReported | -40.50M | -70.92M | -61.67M |
| DilutedAverageShares | 38.28K | 27.70K | 23.67K |
| BasicAverageShares | 38.28K | 27.70K | 23.67K |
| DilutedEPS | -989.44 | -2.65K | -2.80K |
| BasicEPS | -989.44 | -2.65K | -2.80K |
| DilutedNIAvailtoComStockholders | -37.88M | -73.53M | -66.05M |
| NetIncomeCommonStockholders | -37.88M | -73.53M | -66.05M |
| NetIncome | -37.88M | -73.53M | -66.05M |
| NetIncomeIncludingNoncontrollingInterests | -37.88M | -73.53M | -66.05M |
| NetIncomeContinuousOperations | -37.88M | -73.53M | -66.05M |
| PretaxIncome | -37.88M | -73.53M | -66.05M |
| OtherIncomeExpense | 2.49M | -2.73M | -2.89M |
| OtherNonOperatingIncomeExpenses | -2.05M | -3.02M | 230.00K |
| SpecialIncomeCharges | -9.15M | 0.00 | -2.24M |
| OtherSpecialCharges | 9.15M | 2.24M | |
| GainOnSaleOfSecurity | 11.64M | -2.73M | -656.00K |
| NetNonOperatingInterestIncomeExpense | 123.00K | 107.00K | -1.49M |
| InterestExpenseNonOperating | 75.00K | 14.00K | 1.60M |
| InterestIncomeNonOperating | 198.00K | 121.00K | 113.00K |
| OperatingIncome | -40.50M | -70.92M | -61.67M |
| OperatingExpense | 40.50M | 70.92M | 61.67M |
| OtherOperatingExpenses | -2.20M | ||
| ResearchAndDevelopment | 30.12M | 58.62M | 46.65M |
| SellingGeneralAndAdministration | 12.59M | 12.30M | 15.02M |
| GeneralAndAdministrativeExpense | 12.59M | 12.30M | 15.02M |
| OtherGandA | 12.59M | 12.30M | 15.02M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 76.52K | 27.91K | 27.47K |
| ShareIssued | 76.52K | 27.91K | 27.47K |
| NetDebt | 11.22M | 4.52M | |
| TotalDebt | 14.23M | 20.12M | 18.96M |
| TangibleBookValue | -33.51M | -10.61M | 57.32M |
| InvestedCapital | -19.30M | 9.44M | 76.24M |
| WorkingCapital | -33.52M | -2.48M | 75.17M |
| NetTangibleAssets | -33.51M | -10.61M | 57.32M |
| CapitalLeaseObligations | 15.00K | 73.00K | 38.00K |
| CommonStockEquity | -33.51M | -10.61M | 57.32M |
| TotalCapitalization | -33.51M | -2.43M | 75.21M |
| TotalEquityGrossMinorityInterest | -33.51M | -10.61M | 57.32M |
| StockholdersEquity | -33.51M | -10.61M | 57.32M |
| RetainedEarnings | -252.63M | -214.74M | -141.21M |
| AdditionalPaidInCapital | 219.11M | 204.13M | 198.43M |
| CapitalStock | 10.00K | 4.00K | 105.00K |
| CommonStock | 10.00K | 4.00K | 105.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 38.93M | 33.36M | 26.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 8.20M | 17.89M |
| TradeandOtherPayablesNonCurrent | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 8.20M | 17.89M |
| LongTermCapitalLeaseObligation | 0.00 | 15.00K | 0.00 |
| LongTermDebt | 8.18M | 17.89M | |
| CurrentLiabilities | 38.93M | 25.16M | 8.29M |
| OtherCurrentLiabilities | 5.78M | 132.00K | 1.60M |
| CurrentDebtAndCapitalLeaseObligation | 14.23M | 11.92M | 1.07M |
| CurrentCapitalLeaseObligation | 15.00K | 58.00K | 38.00K |
| CurrentDebt | 14.21M | 11.87M | 1.03M |
| OtherCurrentBorrowings | 14.21M | 11.87M | 1.03M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 56.00K | 1.29M | 1.30M |
| PayablesAndAccruedExpenses | 18.86M | 11.81M | 4.32M |
| CurrentAccruedExpenses | 2.46M | 5.99M | 2.42M |
| Payables | 16.40M | 5.82M | 1.89M |
| OtherPayable | 2.19M | 200.00K | |
| AccountsPayable | 16.40M | 3.63M | 1.69M |
| TotalAssets | 5.42M | 22.75M | 83.50M |
| TotalNonCurrentAssets | 15.00K | 72.00K | 39.00K |
| NetPPE | 15.00K | 72.00K | 39.00K |
| GrossPPE | 15.00K | 72.00K | 39.00K |
| BuildingsAndImprovements | 15.00K | 72.00K | 39.00K |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.40M | 22.67M | 83.46M |
| OtherCurrentAssets | 77.00K | 200.00K | 187.00K |
| PrepaidAssets | 1.57M | 6.94M | 4.54M |
| Receivables | 763.00K | 0.00 | |
| AccountsReceivable | 763.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 3.00M | 15.53M | 78.73M |
| CashAndCashEquivalents | 3.00M | 15.53M | 78.73M |
| CashFinancial | 3.00M | 15.53M | 78.73M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -23.91M | -61.60M | -48.99M |
| RepurchaseOfCapitalStock | -1.20M | 0.00 | |
| RepaymentOfDebt | -7.64M | -1.89M | -13.55M |
| IssuanceOfDebt | 0.00 | ||
| IssuanceOfCapitalStock | 20.11M | 457.00K | 118.16M |
| InterestPaidSupplementalData | 505.00K | 11.00K | 10.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 3.00M | 15.53M | 78.73M |
| BeginningCashPosition | 15.53M | 78.73M | 15.66M |
| ChangesInCash | -12.54M | -63.20M | 63.07M |
| FinancingCashFlow | 11.38M | -1.60M | 112.07M |
| CashFlowFromContinuingFinancingActivities | 11.38M | -1.60M | 112.07M |
| NetOtherFinancingCharges | -273.00K | ||
| ProceedsFromStockOptionExercised | 97.00K | 107.00K | 7.46M |
| NetCommonStockIssuance | 18.92M | 457.00K | 118.16M |
| CommonStockPayments | -1.20M | 0.00 | |
| CommonStockIssuance | 20.11M | 457.00K | 118.16M |
| NetIssuancePaymentsOfDebt | -7.64M | -1.89M | -13.55M |
| NetLongTermDebtIssuance | -7.64M | -1.89M | -13.55M |
| LongTermDebtPayments | -7.64M | -1.89M | -13.55M |
| LongTermDebtIssuance | 0.00 | ||
| OperatingCashFlow | -23.91M | -61.60M | -48.99M |
| CashFlowFromContinuingOperatingActivities | -23.91M | -61.60M | -48.99M |
| ChangeInWorkingCapital | 12.42M | 2.78M | -1.41M |
| ChangeInOtherCurrentLiabilities | -58.00K | -1.23M | 0.00 |
| ChangeInPayablesAndAccruedExpense | 7.55M | 6.25M | 1.49M |
| ChangeInAccruedExpense | -4.22M | 3.52M | 1.81M |
| ChangeInPayable | 11.78M | 2.73M | -319.00K |
| ChangeInAccountPayable | 12.78M | 1.93M | -194.00K |
| ChangeInPrepaidAssets | 5.69M | -2.25M | -2.89M |
| ChangeInReceivables | -763.00K | 0.00 | |
| OtherNonCashItems | 6.35M | 4.31M | 6.99M |
| StockBasedCompensation | 3.99M | 5.07M | 8.35M |
| DepreciationAmortizationDepletion | 57.00K | 53.00K | 0.00 |
| DepreciationAndAmortization | 57.00K | 53.00K | 0.00 |
| Depreciation | 57.00K | 53.00K | 0.00 |
| OperatingGainsLosses | -8.84M | -292.00K | 3.12M |
| GainLossOnInvestmentSecurities | -18.00M | -292.00K | 886.00K |
| NetIncomeFromContinuingOperations | -37.88M | -73.53M | -66.05M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SEELQ
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|